middleeast
respiratori
syndrom
coronaviru
merscov
emerg
zoonot
viru
caus
sever
often
fatal
respiratori
ill
human
sinc
first
identif
saudi
arabia
merscov
document
infect
human
steadili
increas
case
februari
estim
lethal
dromedari
camel
natur
reservoir
merscov
zoonot
transmiss
occur
vast
major
dromedari
camel
arabian
peninsula
appear
seroposit
merscov
merscov
strain
found
epidemiologicallylink
human
dromedari
camel
nearli
ident
humantohuman
transmiss
ineffici
occur
upon
close
contact
household
hospit
set
among
patient
patient
healthcar
worker
high
rate
merscov
infect
dromedari
camel
reservoir
pose
persist
threat
reintroduct
merscov
human
despit
continu
threat
public
health
antivir
therapi
vaccin
treat
prevent
merscov
infect
current
lack
viral
spike
surfac
envelop
merscov
virion
primari
antigen
target
develop
vaccin
antibodi
therapi
spike
mediat
viru
entri
host
cell
consist
three
spike
glycoprotein
contain
receptor
bind
subunit
membraneanchor
fusionmedi
subunit
singleparticl
cryoelectron
microscop
analys
trimer
ectodomain
sever
coronavirus
includ
merscov
reveal
multidomain
architectur
subunit
consist
four
core
domain
design
though
merscov
two
spike
domain
engag
host
molecul
ensur
entri
target
cell
domain
merscov
spike
protein
bind
host
receptor
essenti
cell
entri
wherea
ntermin
domain
bind
sialoglycan
mucin
host
cell
surfac
enhanc
infect
merscov
human
lung
cell
three
subunit
form
stem
spike
undergo
extens
conform
chang
enabl
membran
fusion
surfac
subunit
antibodi
bind
show
higher
degre
sequenc
conserv
variabl
subunit
sever
potent
neutral
human
monoclon
antibodi
merscov
develop
use
variou
approach
includ
singl
cell
cultur
method
memori
b
cell
isol
merscov
patient
hybridoma
fusion
bcell
immun
transgen
mice
encod
human
variabl
immunoglobulin
domain
phage
yeast
display
screen
fab
fragment
nonimmun
human
antibodi
librari
antibodi
show
protect
merscov
challeng
anim
model
antibodi
select
base
vitro
neutral
capac
target
merscov
receptor
bind
domain
rbd
structur
function
studi
indic
epitop
antibodi
overlap
bind
site
explain
potent
neutral
capac
far
two
murin
monoclon
antibodi
describ
target
merscov
outsid
rbd
use
combin
dna
protein
vaccin
mice
wang
et
al
describ
nonrbd
neutral
murin
antibodi
show
potenc
protect
merscov
vivo
although
rbdspecif
antibodi
undoubtli
potent
neutral
merscov
effect
antibodi
therapi
like
requir
combin
neutral
nonneutr
antibodi
target
multipl
epitop
exhibit
divers
mechan
action
includ
fcmediat
antibodi
effector
function
addit
antibodi
prefer
human
avoid
immun
reaction
antim
antibodi
differ
speci
identif
protect
antibodi
target
mechan
activ
import
develop
antibodybas
therapi
merscov
studi
develop
set
human
monoclon
antibodi
merscov
divers
mechan
action
show
protect
efficaci
vivo
use
transgen
mice
encod
human
immunoglobulin
variabl
region
gener
antibodi
target
merscov
spike
protein
merss
larg
panel
merssspecif
antibodi
eight
fulli
human
monoclon
antibodi
gener
bind
nonoverlap
epitop
merss
high
affin
interfer
three
known
function
viral
protein
sialic
acid
bind
receptor
bind
membran
fusion
antibodi
shown
protect
mice
lethal
merscov
infect
low
dosag
studi
extend
knowledg
protect
valu
monoclon
antibodi
target
nonrbd
domain
merss
understand
antibodi
contribut
humor
immun
gener
character
panel
human
antibodi
target
differ
function
domain
merscov
spike
protein
develop
human
monoclon
antibodi
mab
employ
transgen
mice
carri
immunoglobulin
transgen
human
variabl
heavi
light
chain
rodent
constant
region
http
wwwharbourbiomedcom
one
immun
experi
mice
immun
purifi
subunit
figur
si
appendix
fig
second
immun
experi
done
gener
antibodi
target
conserv
subunit
use
merss
ectodomain
ectodomain
antigen
follow
sequenti
immun
strategi
figur
si
appendix
figur
hybridoma
cell
line
gener
spleen
lymph
node
deriv
bcell
immun
experi
antibodycontain
hybridoma
supernat
screen
merss
reactiv
elisa
first
immun
experi
provid
hybridoma
supernat
react
understand
immunogen
landscap
subunit
map
epitop
antibodi
domain
individu
domain
express
use
antigen
elisa
si
appendix
figur
major
antibodi
bound
either
domain
figur
b
si
appendix
fig
four
percent
antibodi
bound
either
domain
wherea
antibodi
bind
domain
indic
bind
interdomain
epitop
figur
b
si
appendix
figur
second
immun
merss
ectodomain
ectodomain
result
hybridoma
supernat
hybridoma
posit
bind
merss
ectodomain
elisa
merss
reactiv
antibodi
bound
eight
found
bind
figur
b
viru
neutral
activ
hybridoma
supernat
screen
use
luciferaseencod
merss
pseudotyp
vesicular
stomat
viru
forti
antibodi
mice
neutral
merscov
infect
figur
b
si
appendix
figur
notabl
neutral
antibodi
epitop
map
receptor
bind
domain
two
eight
identifi
antibodi
found
neutral
merss
pseudoviru
figur
b
si
appendix
figur
screen
neutral
antibodi
antigen
bind
competit
identifi
six
epitop
group
use
select
lead
antibodi
si
appendix
figur
set
merscov
specif
antibodi
panel
eight
monoclon
antibodi
mab
select
epitop
distribut
throughout
differ
domain
merscov
spike
protein
detail
biophys
function
character
select
mab
base
uniqu
variabl
heavi
light
chain
sequenc
capac
neutral
merscov
rel
mab
within
epitop
group
si
appendix
figur
could
detect
neutral
antibodi
nevertheless
select
one
nonneutr
mab
recogn
sialic
acidbind
domain
fulli
human
mab
gener
clone
gene
variabl
region
light
heavi
chain
human
express
vector
likewis
express
vector
gener
express
previous
report
potent
merscovneutr
antibodi
antim
control
benchmark
antibodi
addit
use
irrelev
antibodi
recogn
streptag
affin
tag
isotyp
control
reformat
antibodi
express
human
cell
purifi
use
proteina
affin
purif
si
appendix
figur
epitop
map
purifi
human
mab
differ
domain
merscov
done
elisa
use
solubl
merscov
secto
antigen
figur
si
appendix
figur
domainlevel
epitop
map
confirm
mab
bound
sialic
acid
bind
domain
mab
target
receptor
bind
domain
wherea
mab
bound
ectodomain
membran
fusion
subunit
figur
next
competit
bind
lead
antibodi
merss
ectodomain
test
use
biolay
interferometri
figur
b
bind
competit
data
indic
exist
six
epitop
group
suggest
presenc
six
distinct
epitop
target
eight
lead
mab
merscov
protein
group
group
ii
group
iii
domain
group
iv
domain
group
v
group
vi
ectodomain
antibodi
differ
group
compet
minim
indic
epitop
larg
distinct
figur
b
c
bind
kinet
eight
human
monoclon
antibodi
determin
biolay
interferometri
streptag
merss
ectodomain
captur
proteina
sensor
via
antistreptag
antibodi
kinet
bind
paramet
antibodi
determin
ph
antibodi
display
high
affin
bind
merss
ectodomain
equilibrium
dissoci
constant
kd
nano
picomolar
rang
nm
tabl
si
appendix
figur
bind
affin
merscov
receptor
merss
measur
set
lower
compar
bind
affin
mab
target
receptor
bind
domain
tabl
si
appendix
figur
assess
whether
lead
mab
bind
fulllength
merscov
express
cell
surfac
transfect
cell
plasmid
encod
merscov
spike
gene
ctermin
extend
gfp
monitor
merss
express
mutat
furin
cleavag
site
stabil
spike
protein
nativ
prefus
state
prevent
merssmedi
fusion
bind
lead
mab
cellsurfac
express
merss
analys
flow
cytometri
immunofluoresc
antimerss
mab
bound
nonpermeabil
merss
transfect
gfpposit
cell
assay
indic
bind
cell
surfac
display
merscov
si
appendix
figur
abil
human
lead
mab
neutral
merscov
infect
vitro
test
vero
cell
luciferaseencod
merss
pseudotyp
viru
authent
merscov
use
plaqu
reduct
neutral
test
prnt
level
viru
neutral
vari
among
individu
antibodi
figur
tabl
mab
target
epitop
group
show
potent
neutral
activ
display
picomolar
halfmaxim
inhibitori
concentr
merss
pseudotyp
viru
pm
authent
merscov
pm
equival
lower
benchmark
merss
neutral
monoclon
antibodi
target
domain
tabl
mab
epitop
group
ii
mab
iii
mab
neutral
merss
pseudoviru
infect
nanomolar
concentr
nm
resp
exhibit
detect
moder
neutral
activ
authent
merscov
nm
resp
mab
lack
merscov
neutral
activ
viru
neutral
assay
mab
abl
neutral
merss
pseudoviru
nm
resp
albeit
higher
concentr
potent
neutral
mab
higher
isotyp
control
show
neutral
assay
collect
data
demonstr
antibodi
target
receptor
bind
domain
merscov
spike
protein
display
highest
potenti
neutral
merscov
infect
vitro
understand
mechan
action
lead
mab
set
assay
assess
antibodi
interfer
divers
function
merscov
domain
assess
whether
antibodi
compet
viral
bind
host
receptor
develop
elisabas
receptor
bind
inhibit
assay
bind
merss
ectodomain
elisa
plate
quantifi
interfer
receptor
bind
antibodi
measur
reduct
bind
signal
absenc
antibodi
merss
ectodomain
show
stabl
bind
figur
b
wherea
mab
show
weak
interfer
bind
merss
ectodomain
mab
mab
antimersctrl
potent
inhibit
bind
merss
ectodomain
concentrationdepend
manner
figur
b
data
indic
antibodi
partli
overlap
bind
suffici
close
receptorbind
site
compet
receptor
bind
none
antibodi
bind
outsid
rbd
domain
could
block
receptor
bind
potenc
mab
inhibit
receptor
bind
correspond
abil
antibodi
neutral
viru
infect
tabl
indic
inhibit
interact
antibodi
main
mechan
neutral
vitro
recent
demonstr
domain
facilit
viral
bind
cellsurfac
sialoglycoconjug
serv
cell
attach
factor
merscov
assess
whether
mab
interfer
bind
sialoglycoconjug
surfac
erythrocyt
use
hemagglutin
inhibit
assay
end
use
lumazin
synthas
ls
nanoparticl
multival
display
earlier
employ
demonstr
sialicacid
depend
hemagglutin
domain
hemagglutin
observ
mix
erythrocyt
figur
mediat
hemaglutin
abrog
upon
addit
mab
upon
addit
isotyp
control
next
assess
whether
interfer
bind
sialyl
receptor
could
inhibit
siadepend
merscov
infect
bind
sialoglycan
may
aid
merscov
entri
cell
depend
cell
type
infect
vero
cell
depend
cell
surfac
sialic
acid
concurr
low
abund
merscov
glycotop
cell
correspondingli
infect
vero
cell
merss
pseudoviru
could
inhibit
figur
b
contrast
infect
human
lung
cell
shown
reli
cell
surfac
sialic
acid
correl
abund
merscov
receptor
contrari
vero
cell
infect
cell
could
inhibit
figur
b
suggest
antibodi
bind
neutral
merscov
infect
via
inhibit
viru
bind
cell
surfac
sialoglycan
coronaviru
subunit
encompass
machineri
fusion
viral
host
cell
membran
process
driven
extens
refold
metast
prefus
stabl
postfus
state
hypothes
antibodi
target
subunit
might
neutral
merscov
infect
inhibit
fusion
process
test
develop
merscov
driven
fusion
assay
use
modifi
merscov
spike
protein
monitor
express
merscov
cell
extend
viral
fusion
protein
ctermin
gfp
addit
mutat
furin
cleavag
site
junction
increas
depend
merscov
fusion
activ
exogen
addit
trypsin
express
merss
variant
upon
transfect
cell
could
readili
observ
gfp
signal
figur
c
upon
addit
trypsin
larg
gfpfluoresc
syncytia
detect
indic
merss
mediat
fusion
figur
c
expect
addit
block
format
syncytia
sinc
fusion
depend
receptor
interact
effect
syncytium
format
seen
mab
contrast
mab
block
syncytium
format
sinc
neutral
antibodi
interfer
receptor
bind
figur
b
surmis
bind
antibodi
inhibit
infect
prevent
conform
chang
subunit
merscov
spike
protein
requir
fusion
assess
prophylact
efficaci
lead
mab
merscov
infect
vivo
use
transgen
mice
express
human
six
hour
prior
merscov
infect
mice
micegroup
inject
intraperiton
dose
mab
equival
mg
mab
per
kg
bodi
weight
percentag
surviv
weight
chang
follow
challeng
monitor
day
merscov
infect
consist
lethal
mice
receiv
monoclon
isotyp
control
show
signific
weight
loss
succumb
infect
day
postchalleng
figur
b
contrarili
bind
mab
show
high
level
protect
lethal
merscov
challeng
figur
mab
benchmark
antim
control
mab
uniformli
protect
anim
death
wherea
mab
protect
anim
model
bind
mab
afford
partial
protect
mortal
notabl
mab
protect
five
anim
lethal
infect
rel
isotyp
control
treat
mice
mice
treat
merss
specif
antibodi
show
reduc
weight
loss
figur
b
result
highlight
antibodi
target
nonrbd
domain
ic
merscov
spike
protein
contribut
humor
immun
merscov
infect
recur
spillov
infect
merscov
human
dromedari
camel
reservoir
high
mortal
persontoperson
transmiss
pose
signific
threat
public
health
current
licens
vaccin
treatment
combat
merscov
infect
develop
effect
counter
measur
critic
need
recent
priorit
world
health
organ
research
develop
blueprint
action
prevent
epidem
antibodi
therapi
target
critic
entri
function
viral
glycoprotein
increasingli
recogn
promis
antivir
strategi
protect
human
lethal
diseas
merscov
passiv
immun
studi
neutral
antibodi
small
anim
support
idea
antibodi
therapi
may
hold
promis
protect
human
lethal
merscov
mediat
diseas
protect
antibodi
neutral
viru
infect
occupi
receptor
bind
domain
rbd
compet
host
receptor
describ
protect
activ
individu
human
antibodi
target
rbd
well
nonrbd
spike
domain
interfer
three
known
function
spike
glycoprotein
collect
arsen
protect
antibodi
bind
function
inhibit
activ
multipl
spike
protein
domain
reveal
new
way
gain
humor
protect
emerg
mer
coronaviru
potent
merscov
neutral
antibodi
studi
other
shown
commonli
target
receptor
bind
domain
antibodi
physic
prevent
bind
host
receptor
attribut
higher
bind
affin
merss
therebi
potent
neutral
merscov
infect
five
antibodi
identifi
studi
found
target
three
nonoverlap
epitop
group
merscov
domain
consist
three
epitop
group
receptor
interfac
report
tang
et
al
antibodi
display
vari
neutral
potenc
differ
valu
antibodi
target
epitop
group
show
ultrapot
neutral
activ
subnanomolar
level
irrespect
neutral
potenc
antibodi
display
signific
protect
activ
surviv
rate
mice
lethal
merscov
challeng
apart
engag
host
receptor
earlier
demonstr
merscov
spike
protein
bind
sialoglycoconjug
sia
mucin
host
cell
surfac
via
independ
function
domain
ntermin
domain
siabind
activ
serv
attach
factor
merscov
infect
celltyp
depend
manner
show
bind
isol
mab
domain
abrog
siabind
inhibit
siadepend
infect
human
lung
cell
merscov
moreov
passiv
immun
mice
mab
result
protect
mortal
follow
merscov
infect
find
underlin
role
sialic
acid
bind
merscov
infect
vivo
demonstr
import
antibodi
protect
merscov
mab
describ
two
mab
target
epitop
outsid
rbd
bind
epitop
outsid
rbd
wherea
target
variabl
loop
wang
murin
antibodi
shown
protect
mice
lethal
infect
merscov
vivo
antibodi
neutral
though
interfer
antibodi
spike
function
delin
use
tailor
immun
scheme
boost
antibodi
respons
merscov
fusionmedi
subunit
abl
recov
mab
two
demonstr
neutral
activ
fulli
protect
mice
lethal
merscov
challeng
two
antibodi
interfer
receptor
bind
yet
abrog
fusion
impli
interfer
spikemedi
membran
fusion
prevent
conform
chang
requir
fusion
highli
protect
mab
display
modest
vitro
neutral
activ
indic
strong
neutral
activ
prerequisit
protect
apart
interf
function
viral
protein
antibodi
abl
employ
broad
rang
antivir
activ
innat
immun
system
bind
antibodi
glycoprotein
surfac
infect
cell
virus
may
decor
destruct
fcmediat
antivir
activ
includ
antibodydepend
cellular
cytotox
adcc
antibodydepend
cellmedi
phagocytosi
adcp
complementdepend
cytotox
cdc
function
may
irrespect
neutral
capac
antibodi
long
bind
surfac
antigen
infect
cell
congruent
prerequisit
antimerss
antibodi
abl
bind
cell
surfac
display
spike
addit
human
antibodi
isotyp
shown
potent
human
igg
isotyp
mice
show
effici
bind
activ
mous
receptor
induct
adccadcp
mous
natur
killer
cell
mous
macrophag
research
need
defin
contribut
fcfunction
antibodymedi
protect
merscov
infect
identifi
human
antibodi
target
six
distinct
epitop
class
across
differ
domain
merscov
spike
protein
show
protect
activ
mice
lethal
merscov
challeng
discoveri
hold
promis
develop
antibodi
therapeut
merscov
infect
passiv
immun
combin
antibodi
target
differ
domain
function
viral
glycoprotein
might
protect
viru
infect
singl
epitop
mab
therapi
shown
envelop
rna
virus
combin
antibodi
provid
synergist
protect
activ
merscov
combin
epitop
best
target
need
evalu
addit
combin
antibodi
target
distinct
epitop
mitig
viral
antigen
escap
demonstr
number
virus
includ
merscov
particularli
use
combin
antibodi
target
conserv
epitop
spike
glycoprotein
critic
viral
entri
may
decreas
chanc
escap
mutant
antibodi
may
well
offer
crossprotect
relat
virus
antibodi
target
conserv
epitop
stem
region
glycoprotein
envelop
viru
includ
influenza
viru
ebolaviru
offer
protect
wide
rang
antigen
distinct
variant
likewis
gener
antibodi
target
conserv
stem
coronaviru
spike
protein
crossbind
spike
relat
coronavirus
may
even
allow
develop
mab
broad
protect
relat
futur
emerg
coronavirus
furthermor
import
antibodi
describ
complet
human
import
advantag
use
sever
time
host
without
invok
immun
respons
antibodi
may
requir
peopl
work
camel
infect
patient
final
presenc
protect
antibodi
epitop
multipl
spike
domain
suggest
multidomain
approach
spikebas
vaccin
may
provid
broader
repertoir
immun
respons
compar
rbdfocus
vaccin
antigen
reduc
risk
antigen
escap
studi
also
defin
differ
correl
humor
protect
may
need
consid
evalu
vaccineinduc
immun
respons
product
recombin
merscov
protein
gene
encod
merscov
spike
glycoprotein
emc
isol
genbank
synthes
genscript
usa
inc
sequenc
codonoptim
maxim
express
baculoviru
express
system
produc
solubl
merss
ectodomain
gene
fragment
encod
merscov
ectodomain
amino
acid
clone
infram
honeybe
melittin
hbm
secret
signal
peptid
fibritin
foldon
trimer
domain
follow
streptag
purif
tag
pfastbac
transfer
vector
invitrogen
furin
cleavag
site
junction
mutat
ksvr
prevent
cleavag
furin
posit
gene
encod
subunit
amino
acid
ectodomain
amino
acid
amino
acid
clone
infram
hbm
secret
signal
peptid
tripl
streptag
purif
tag
pfastbac
transfer
vector
gener
bacmid
dna
recombin
baculoviru
perform
accord
protocol
bactobac
system
invitrogen
express
merscov
variant
perform
infect
recombin
baculoviru
cell
recombin
protein
harvest
cell
cultur
supernat
day
post
infect
purifi
use
streptactin
sepharos
affin
chromatographi
iba
solubl
merss
ectodomain
use
immun
produc
drosophila
express
system
describ
clone
gene
insert
pfastbac
transfer
vector
pmt
express
vector
invitrogen
thermo
fisher
scientif
netherland
product
recombin
amino
acid
use
immun
solubl
describ
previous
brief
amino
acid
encod
sequenc
ctermin
fuse
gene
fragment
encod
fc
region
human
igg
clone
pcagg
mammalian
express
vector
express
plasmid
transfect
cell
affin
purifi
cultur
supernat
use
proteina
affin
chromatographi
fc
part
fusion
protein
proteolyt
remov
thrombin
follow
proteina
affin
purif
use
thrombin
cleavag
site
present
junction
sequenc
encod
human
ectodomain
amino
acid
ntermin
fuse
streptag
purif
tag
clone
pcagg
vector
express
plasmid
transfect
cell
purifi
cell
cultur
supernat
use
streptactin
sepharos
affin
chromatographi
product
lumazin
synthas
ls
nanoparticl
display
merscov
spike
domain
describ
previous
brief
encod
sequenc
residu
ntermin
fuse
signal
peptid
sequenc
follow
streptag
purif
tag
sequenc
iba
ctermin
fuse
lumazin
synthaseencod
sequenc
aquifex
aeolicu
genbank
via
glyser
linker
subsequ
clone
pcagg
vector
express
cell
purifi
cell
cultur
supernat
use
streptactin
affin
chromatographi
product
recombin
monoclon
antibodi
recombin
mab
product
cdna
encod
variabl
heavi
vh
light
vl
chain
region
antimerss
mab
clone
express
plasmid
contain
human
heavi
chain
ig
kappa
light
chain
constant
region
respect
invivogen
plasmid
contain
signal
sequenc
enabl
effici
secret
recombin
antibodi
synthet
vh
vl
gene
fragment
benchmark
antibodi
mersctrl
synthezis
base
previous
describ
sequenc
merss
monoclon
antibodi
recombin
human
antimerss
antibodi
produc
cell
follow
transfect
pair
heavi
light
chain
express
plasmid
accord
protocol
invivogen
antibodi
purifi
tissu
cultur
supernat
use
proteina
affin
chromatographi
purifi
antibodi
store
use
gener
antimerss
mab
two
group
six
mice
immun
two
week
interv
six
time
purifi
group
merss
ectodomain
follow
ectodomain
group
ii
outlin
figur
antigen
inject
use
stimun
adjuv
prionic
freshli
prepar
accord
manufactur
instruct
first
inject
boost
done
use
ribi
sigma
adjuv
inject
done
subcutan
left
right
groin
intraperiton
four
day
last
inject
spleen
lymph
node
harvest
hybridoma
made
standard
method
use
sp
myeloma
cell
line
atcc
fusion
partner
hybridoma
screen
antigenspecif
elisa
select
develop
subclon
produc
small
scale
ml
medium
purpos
hybrydoma
cultur
serum
proteinfre
medium
hybridoma
cultur
pfhmii
gibco
addit
nonessenti
amino
acid
neaa
biowhittak
lonza
cat
antibodi
purifi
cell
supernat
use
prote
affin
chromatographi
purifi
antibodi
store
use
merss
pseudotyp
viru
neutral
assay
product
vsv
pseudotyp
merss
perform
describ
previous
adapt
briefli
cell
transfect
pcagg
express
vector
encod
merss
carri
cytoplasm
tail
truncat
one
day
post
transfect
cell
infect
vsvg
pseudotyp
bear
firefli
photinu
pyrali
luciferas
report
gene
twenti
four
hour
later
pseudotyp
harvest
titrat
african
green
monkey
kidney
vero
cell
viru
neutral
assay
merss
mab
serial
dilut
two
time
desir
final
concentr
dmem
supplement
foetal
calf
serum
bodinco
uml
penicillin
streptomycin
dilut
mab
incub
equal
volum
pseudotyp
h
room
temperatur
inocul
confluent
vero
monolay
plate
incub
h
luciferas
activ
measur
berthold
centro
lb
plate
luminomet
use
dluciferin
substrat
promega
percentag
infect
calcul
ratio
luciferas
readout
presenc
mab
normal
luciferas
readout
absenc
mab
half
maxim
inhibitori
concentr
determin
use
logist
regress
graphpad
prism
merscov
neutral
assay
neutral
authent
merscov
perform
use
plaqu
reduct
neutral
test
prnt
describ
earlier
brief
mab
twofold
serial
dilut
mix
merscov
h
mixtur
ad
cell
incub
hr
cell
wash
incub
medium
h
subsequ
cell
wash
fix
permeabil
infect
detect
use
immunofluoresc
stain
prnt
titr
determin
highest
mab
dilut
result
reduct
number
infect
cell
elisa
analysi
merscov
bind
antibodi
nunc
maxisorp
plate
thermo
scientif
coat
indic
merscov
antigen
ng
well
overnight
plate
wash
three
time
phosphat
salin
buffer
pb
contain
block
bovin
serum
albumin
bsa
pb
contain
room
temperatur
h
fourfold
serial
dilut
mab
start
dilut
block
buffer
ad
plate
incub
h
room
temperatur
plate
wash
three
time
incub
hrpconjug
goat
antihuman
secondari
antibodi
itk
southern
biotech
dilut
block
buffer
one
hour
room
temperatur
hrp
activ
measur
nm
use
tetramethylbenzidin
substrat
biofx
elisa
plate
reader
biotek
elisa
analysi
receptor
bind
inhibit
antibodi
recombin
solubl
coat
nunc
maxisorp
plate
thermo
scientif
overnight
plate
wash
three
time
pb
contain
block
bsa
pb
contain
room
temperatur
h
recombin
merscov
ectodomain
serial
dilut
antim
mab
mix
h
rt
ad
plate
h
room
temperatur
plate
wash
three
time
bind
merscov
ectodomain
detect
use
hrpconjug
antistrepmab
iba
recogn
streptag
affin
tag
merscov
ectodomain
detect
hrp
activ
perform
describ
antibodi
competit
assay
competit
among
mab
bind
epitop
merscov
determin
use
biolay
interferometri
bli
octet
qk
pall
fortebio
reagent
dilut
pb
assay
perform
follow
step
antistrep
mab
coat
protein
biosensor
pall
fortebio
min
block
sensor
rabbit
igg
min
recombin
streptag
merscov
ectodomain
immobil
sensor
min
addit
mab
min
allow
satur
bind
immobil
antigen
addit
mab
min
first
antibodi
mab
taken
along
verifi
satur
bind
wash
step
pb
includ
step
bind
kinet
affin
measur
bind
kinet
affin
mab
merss
ectodomain
measur
bli
use
octet
qk
optim
load
concentr
antimerss
mab
onto
antihuman
fc
biosensor
pall
fortebio
predetermin
avoid
satur
sensor
kinet
bind
assay
perform
load
antim
mab
optim
concentr
nm
antihuman
fc
biosensor
min
antigen
associ
step
perform
incub
sensor
rang
concentr
recombin
merss
ectodomain
nm
min
follow
dissoci
step
pb
min
kinet
constant
calcul
use
langmuir
bind
model
fortebio
data
analysi
softwar
hemagglutin
inhibit
assay
potenc
mab
inhibit
hemagglutin
lumazin
synthas
nanoparticl
perform
describ
previous
slight
modif
twofold
serial
dilut
pb
contain
bovin
serum
albumin
bsa
mix
human
erythrocyt
vbottom
plate
greiner
bioon
incub
h
hemagglutin
titr
score
concentr
result
hemagglutin
unit
determin
subsequ
twofold
serial
dilut
antimerss
mab
pb
contain
bsa
mix
hemagglutin
unit
vbottom
plate
min
incub
room
temperatur
human
erythrocyt
ad
final
concentr
vv
mixtur
incub
h
hemagglutin
inhibit
activ
antimerss
mab
score
fusion
inhibit
assay
cell
seed
densiti
cell
per
ml
reach
confluenc
cell
transfect
express
plasmid
encod
full
length
merscov
fuse
green
fluoresc
protein
gfp
use
polyplu
transfect
new
york
usa
cat
furin
recognit
site
merscov
mutat
inhibit
cleavag
protein
two
day
post
transfect
cell
treat
trypsin
activ
merscov
spike
fusion
function
presenc
absenc
antimerss
mab
incub
h
cell
fix
incub
paraformaldehyd
pb
min
room
temperatur
stain
nuclei
dapi
cell
express
merscov
detect
fluoresc
microscopi
use
ctermin
append
gfp
merscov
smediat
fusion
observ
format
fluoresc
multinucl
syncytia
fluoresc
imag
record
use
evo
fl
fluoresc
microscop
thermo
fisher
scientif
netherland
antibodymedi
protect
mice
challeng
merscov
vivo
efficaci
mab
specif
protein
merscov
isotyp
match
neg
control
mab
evalu
protect
transgen
mous
model
express
receptor
human
merscov
suscept
virul
viru
merscov
intranas
infect
transgen
mice
express
human
caus
lethal
diseas
associ
enceph
lung
mononuclear
cell
infiltr
alveolar
oedema
microvascular
thrombosi
airway
gener
unaffect
test
prophylact
efficaci
mab
vivo
group
mice
week
old
given
mg
antibodi
per
kg
mous
intraperiton
inject
h
intranas
infect
lethal
dose
merscov
emc
isol
pfumous
challeng
dose
result
consist
lethal
infect
untreat
mice
wherea
administ
dose
consist
lethal
mice
receiv
isotyp
control
antibodi
mice
receiv
best
viru
neutral
antibodi
fulli
protect
